Industry news that matters to you.  Learn more

Archives for November 2015

Investigational Blood Test Identifies Patients with Melanoma Who Are More Likely to Have Improved Survival on Nivolumab Therapy; Biodesix’ Blood Test is Independent of PD-L1 Expression

Biodesix, Inc. recently announced new clinical findings showing that its novel investigational test, BDX008, based on profiling serum proteins, identifies patients with advanced melanoma who are more likely to have longer progression-free and overall survival with nivolumab therapy.[1] Early data suggesting the test’s clinical potential for guiding anti-PD-1 therapy is being presented at the 30th annual meeting of the Society for Immunotherapy of Cancer (SITC) in National Harbor, MD.

International Team Launches Community Competition to Understand Tumor Origins and Evolution

An international consortium of groups from Canada, the United States and the United Kingdom have come together to create an innovative, cloud-based, public challenge running on the Google Cloud Platform to optimize the discovery of genetically distinct groups of cells within cancers that could respond differently to treatment and have different risk of spreading. The ICGC-TCGA DREAM Somatic Mutation Calling Heterogeneity (SMC-Het) Challenge is the first project in the world to marry crowd-sourced benchmarking and cloud-based execution of DNA sequencing analysis pipelines to improve our understanding of tumour DNA. The Challenge launched on November 16, 2015 and will run until May 2016. Sign up to participate at: https://www.synapse.org/SMCHet.

ViaCyte Licenses Cell Differentiation Technology to Takara Bio Inc.

ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the treatment of diabetes in clinical-stage development, today announced that the Company has entered into a non-exclusive licensing agreement with Takara Bio, Inc. Takara will utilize certain portions of ViaCyte’s cell differentiation technology to expand its stem cell product line, marketed under the Cellartis® brand. Takara will make the technology available for research purposes only, not for clinical or commercial application.

An Innovative Sample Management Partnership with the Crohn’s & Colitis Foundation is Advancing Precision Medicine Through Novel Research to Find a Cure for IBD

As the global leader in comprehensive sample management solutions, BioStorage Technologies has entered into a strategic partnership with the  (CCFA) to provide innovative sample management and transformative technology services across the entire sample lifecycle including logistics, kitting, bioprocessing, storage and distribution of samples for its new IBD Plexus initiative.

The Icahn School of Medicine at Mount Sinai Uses Ayasdi for Data Analysis to Identify Subtypes of Diabetes in an Advance for Precision Medicine

Ayasdi today announced the publication of a major new finding on the sub-typing of type 2 diabetes by long-time collaborator, the Icahn School of Medicine at Mount Sinai. The findings, published in the prestigious Science journal, Science Translational Medicine, demonstrates that with the right data, technologies and researchers, precision medicine can become a reality.